Literature DB >> 33024484

Extreme Obesity is Associated with Low Success Rate of Atrial Fibrillation Catheter Ablation.

Toshimasa Okabe1, Benjamin Buck1, Samuel A Hayes1, Thura T Harfi1, Muhammad R Afzal1, Jaret Tyler1, Mahmoud Houmsse1, Steven J Kalbfleisch1, Raul Weiss1, John D Hummel1, Ralph S Augostini1, Emile G Daoud1.   

Abstract

BACKGROUND: Catheter ablation (CA) is an established treatment for patients with symptomatic atrial fibrillation (AF). The purpose of this study was to evaluate the safety and efficacy of single CA in AF patients with extreme obesity (body mass index [BMI] ≥ 40 kg/m2) and its long-term impact on body weight.
METHODS: Patients with BMI ≥40 kg/m2 who underwent CA at the Ohio State University between 2012 and 2016 were included. The primary efficacy endpoint was no atrial arrhythmia lasting > 30 seconds without anti-arrhythmic drugs during 1-year follow-up after a single procedure.
RESULTS: Out of 230 AF patients with BMI ≥ 40 kg/m2 undergoing CA, pulmonary vein isolation was achieved in 226 (98%) patients.Seventeen patients (7.4%) experienced acute major complications, including pericardial effusion, vascular complications and respiratory failure. Patient characteristics for 135 patients with complete 1-year follow-up were as follows: mean age 58.6 ± 9.6 years, mean BMI 44.5±4.7 kg/m2, female 63 (47%), non-paroxysmal AF 100 (74%), median CHA2DS2-VASc score 2 (IQR:1-3). In this cohort, the primary efficacy endpoint was achieved in 44 (33%) patients. Paroxysmal AF was associated with higher CA success compared to non-paroxysmal (51 vs. 26% [p < 0.01]).There was no significant weight change even in patients with successful AF CA.
CONCLUSIONS: Extreme obesity is associated with low AF CA success, particularly in those with non-paroxysmal AF. Successful AF CA was not associated with long-term weight reduction. A better treatment strategy is needed in this population of AF and extreme obesity.

Entities:  

Keywords:  Atrial fibrillation; Body mass index; Catheter ablation; Obesity

Year:  2020        PMID: 33024484      PMCID: PMC7533126          DOI: 10.4022/jafib.2242

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  39 in total

Review 1.  Efficacy and safety of atrial fibrillation ablation with phased radiofrequency energy and multielectrode catheters.

Authors:  Jason G Andrade; Marc Dubuc; Lena Rivard; Peter G Guerra; Blandine Mondesert; Laurent Macle; Bernard Thibault; Mario Talajic; Denis Roy; Paul Khairy
Journal:  Heart Rhythm       Date:  2011-09-09       Impact factor: 6.343

2.  Approaches to catheter ablation for persistent atrial fibrillation.

Authors:  Atul Verma; Chen-yang Jiang; Timothy R Betts; Jian Chen; Isabel Deisenhofer; Roberto Mantovan; Laurent Macle; Carlos A Morillo; Wilhelm Haverkamp; Rukshen Weerasooriya; Jean-Paul Albenque; Stefano Nardi; Endrj Menardi; Paul Novak; Prashanthan Sanders
Journal:  N Engl J Med       Date:  2015-05-07       Impact factor: 91.245

Review 3.  Obesity and Cardiovascular Disease.

Authors:  Francisco B Ortega; Carl J Lavie; Steven N Blair
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

4.  PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study.

Authors:  Melissa E Middeldorp; Rajeev K Pathak; Megan Meredith; Abhinav B Mehta; Adrian D Elliott; Rajiv Mahajan; Darragh Twomey; Celine Gallagher; Jeroen M L Hendriks; Dominik Linz; R Doug McEvoy; Walter P Abhayaratna; Jonathan M Kalman; Dennis H Lau; Prashanthan Sanders
Journal:  Europace       Date:  2018-12-01       Impact factor: 5.214

5.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.

Authors:  Jens Cosedis Nielsen; Arne Johannessen; Pekka Raatikainen; Gerhard Hindricks; Håkan Walfridsson; Ole Kongstad; Steen Pehrson; Anders Englund; Juha Hartikainen; Leif Spange Mortensen; Peter Steen Hansen
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

6.  The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study.

Authors:  Jan Stritzke; Marcello Ricardo Paulista Markus; Stefanie Duderstadt; Wolfgang Lieb; Andreas Luchner; Angela Döring; Ulrich Keil; Hans-Werner Hense; Heribert Schunkert
Journal:  J Am Coll Cardiol       Date:  2009-11-17       Impact factor: 24.094

7.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.

Authors:  Carlos A Morillo; Atul Verma; Stuart J Connolly; Karl H Kuck; Girish M Nair; Jean Champagne; Laurence D Sterns; Heather Beresh; Jeffrey S Healey; Andrea Natale
Journal:  JAMA       Date:  2014-02-19       Impact factor: 56.272

Review 8.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities.

Authors:  Michele Cavalera; Junhong Wang; Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2014-05-10       Impact factor: 7.012

9.  Impact of overweight and obesity on left ventricular diastolic function and value of tissue Doppler echocardiography.

Authors:  Antoine Kossaify; Nayla Nicolas
Journal:  Clin Med Insights Cardiol       Date:  2013-02-21

10.  The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity.

Authors:  J J Rayner; R Banerjee; C J Holloway; A J M Lewis; M A Peterzan; J M Francis; S Neubauer; O J Rider
Journal:  Int J Obes (Lond)       Date:  2017-10-04       Impact factor: 5.095

View more
  1 in total

Review 1.  [Metabolic syndrome and atrial fibrillation].

Authors:  Bernd Nowak; Boris Schmidt; Shaojie Chen; Lukas Urbanek; Stefano Bordignon; David Schaack; Shota Tohoku; Julian Chun
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.